Last reviewed · How we verify

Delalutin (HYDROXYPROGESTERONE CAPROATE)

Bristol-Myers Squibb · FDA-approved withdrawn Small molecule Quality 60/100

Delalutin (HYDROXYPROGESTERONE CAPROATE) is a progestin medication originally developed by ACTAVIS LABS UT INC and currently owned by Bristol Myers Squibb. It targets corticosteroid-binding globulin and is used to prevent premature labor. Delalutin is a small molecule drug that has been FDA-approved since 1975 and is available as a generic medication. It is off-patent and has multiple generic manufacturers. Key safety considerations include the potential for adverse effects on the fetus and mother during pregnancy.

At a glance

Generic nameHYDROXYPROGESTERONE CAPROATE
SponsorBristol-Myers Squibb
Drug classProgestin
TargetCorticosteroid-binding globulin
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved
First approval1975

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results